Erika Ivett U.
- Country
- Hungary
- Department
- N/A
Research Overview
- Long-term safety and efficacy of subcutaneous lunsekimig in adults with asthma: An open-label extension study
- Evaluation of Dupilumab's Long-term Impact on Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma: A Randomized, Double-blind, Placebo-controlled Study
- Efficacy and Safety Evaluation of Subcutaneous Amlitelimab in Adults with Moderate-to-Severe Asthma: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 102 of 227 partner sites.
Specializations
Respiratory Medicine
Erika UNGER is strongly involved in clinical research on asthma, chronic obstructive pulmonary disease (COPD), and chronic bronchitis, with additional interest in refractory chronic cough and severe eosinophilic airway disease. Her trial portfolio also includes studies in lung function, exacerbation control, and long-term respiratory disease management.
- Moderate-to-severe asthma
- Severe uncontrolled asthma
- COPD and chronic bronchitis
- Refractory chronic cough
Her research activity reflects a clear focus on advanced inhaled and biologic therapies for persistent airway inflammation and symptom burden.
Atopic and Immune-Mediated Skin Disease
Her work includes atopic dermatitis across adult and pediatric populations, as well as nonsegmental vitiligo. These studies place emphasis on immune-mediated skin conditions requiring targeted anti-inflammatory treatment and durable disease control.
- Moderate-to-severe atopic dermatitis
- Children with atopic eczema
- Nonsegmental vitiligo
She is active in therapeutic areas where systemic immunomodulation is central to improving chronic dermatologic disease outcomes.
Cardiovascular and Thromboembolic Risk
Erika UNGER is engaged in studies addressing cardiovascular disease, atherosclerotic cardiovascular disease (ASCVD), atrial fibrillation, and prevention of stroke and systemic embolism. Her portfolio also extends to cardiometabolic risk associated with obesity and elevated lipoprotein-related risk.
- Atrial fibrillation and stroke prevention
- Atherosclerotic cardiovascular disease
- Cardiovascular outcomes in obesity
- Lipoprotein(a)-related risk
Her research interests align with therapies aimed at reducing major cardiovascular events and improving long-term vascular protection.
Metabolic, Renal, and Liver Disease
Her clinical trial activity includes chronic kidney disease (CKD) with hypertension, non-alcoholic steatohepatitis (NASH), and obesity. These areas highlight involvement in cardiometabolic and organ-protective treatment strategies across renal and hepatic disease.
- CKD with hypertension
- Non-alcoholic steatohepatitis
- Obesity and overweight
She contributes to research focused on slowing disease progression in metabolic and organ-complication settings.
Endocrine and Diagnostic Imaging
Erika UNGER also participates in research on Graves’ disease and on magnetic resonance imaging contrast enhancement for both central nervous system pathology and non-central nervous system indications. This adds an endocrine and imaging dimension to her clinical research profile.
- Graves’ disease
- MRI contrast enhancement for CNS pathology
- MRI contrast enhancement for non-CNS pathology
Her involvement spans immune-endocrine treatment development and diagnostic innovation in radiologic assessment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.